Stopped manufacturing Covishield since December 2021, says Serum Institute
7 months, 2 weeks ago

Stopped manufacturing Covishield since December 2021, says Serum Institute

Hindustan Times  

Pune-based Serum Institute of India stopped manufacturing its anti-Covid-19 vaccine Covishield in 2021, according to a statement issued by the company on Wednesday after British-Swedish pharmaceutical manufacturer AstraZeneca announced it was withdrawing its vaccine against Covid, Vaxzevria, due to “commercial reasons” as demand for it decreased globally. Consequently, since December 2021, we have stopped the manufacturing and supply of additional doses of Covishield,” an SII spokesperson said in the statement. The AstraZeneca’s recent disclosure in UK Court about its anti-Covid19 vaccine causing Thrombosis with Thrombocytopenia Syndrome “in very rare cases” created uproar. The Daily Telegraph reported that in a legal document submitted to the high court in London in February for a class action being fought, AstraZeneca admitted that their vaccine developed in partnership with the University of Oxford to protect against Covid-19 may cause Thrombosis with TTS in “very rare cases”.

India Vaccines Syndrome Ema 2021 Serum Institute Of India Serum Institute Covishield Sii Tts Vaxzevria Thrombocytopenia Syndrome Stopped Manufacturing Thrombocytopenia Thrombosis Covid19 Vaccine  covid19  vaccine  stopped  manufacturing  serum  pandemic  syndrome  institute  thrombocytopenia  thrombosis  covishield  rare  2021  vaccines

History of this topic

AstraZeneca's Covid vaccine linked to another rare blood disorder
7 months, 1 week ago

AstraZeneca's Covid vaccine linked to another rare blood disorder

India Today  

Over a week after AstraZeneca announced a global withdrawal of its vaccine against coronavirus citing a slowdown in sales and availability of enough options in the market, new research has linked it to a rare disorder. Researchers found that the AstraZeneca vaccine, sold in India under the brand name Covishield, is linked to a rare blood clotting disorder called Vaccine-Induced …

Covishield Side Effects: Doctors' Group Urges Govt to Review All Covid Vaccines
7 months, 1 week ago

Covishield Side Effects: Doctors' Group Urges Govt to Review All Covid Vaccines

News 18  

In the wake of pharmaceutical giant AstraZeneca admitting in a UK court that its Covid vaccine can cause blood clots in rare cases, a group of doctors on Thursday expressed deep concern over the safety of the Covishield vaccine manufactured by the Serum Institute of India. At a press conference, the doctors, under the banner of the Awaken India Movement, …

AstraZeneca withdraws Covishield pointing to low demand, but did rare side effects also play a role?
7 months, 2 weeks ago

AstraZeneca withdraws Covishield pointing to low demand, but did rare side effects also play a role?

The Hindu  

Published : May 09, 2024 13:21 IST - 3 MINS READ The pharmaceutical giant AstraZeneca has reportedly withdrawn its COVID-19 vaccine Vaxzevria, also known as Covishield, worldwide, citing commercial reasons for the decision. Vaxzevria saved millions of lives AstraZeneca, who developed the vaccine with Oxford University, said it was “incredibly proud of the role Vaxzevria played in ending the global …

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official
7 months, 2 weeks ago

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official

News 18  

AstraZeneca’s vaccine has demonstrated the lowest incidence of side effects in India compared to the global average, a top government official involved in the national roll-out of Covid-19 vaccination told News18. “But only around 50 cases witnessed Thrombosis with Thrombocytopenia Syndrome — a rare side effect caused by the jab — of the 180 crore doses administered against 4 to …

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021
7 months, 2 weeks ago

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021

Live Mint  

New Delhi: The Serum Institute of India on Wednesday said it has stopped making and supplying covid-19 vaccine Covishield after AstraZeneca, the British drugmaker that helped develop the vaccine, announced it too was withdrawing its version of the jab worldwide. The development follows the launch of a class action suit in the UK over allegations that the UK vaccine caused …

AstraZeneca withdraws Covid vaccine worldwide after admitting it can cause rare blood clots
7 months, 2 weeks ago

AstraZeneca withdraws Covid vaccine worldwide after admitting it can cause rare blood clots

The Independent  

The best of Voices delivered to your inbox every week - from controversial columns to expert analysis Sign up for our free weekly Voices newsletter for expert opinion and columns Sign up to our free weekly Voices newsletter Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, …

As AstraZeneca announces vaccine withdrawal, Serum Institute says stopped Covishield in 2021
7 months, 2 weeks ago

As AstraZeneca announces vaccine withdrawal, Serum Institute says stopped Covishield in 2021

New Indian Express  

NEW DELHI: Days after AstraZeneca admitted for the first time in court documents that their Covid-19 vaccine can cause a rare and dangerous side effect, the British pharma giant announced that they are withdrawing it globally. In its statement, AstraZeneca said, "As multiple, variant COVID-19 vaccines have since been developed, there is a surplus of available updated vaccines. According to …

AstraZeneca withdraws COVID-19 vaccine citing a decline in demand
7 months, 2 weeks ago

AstraZeneca withdraws COVID-19 vaccine citing a decline in demand

ABC  

In short: Pharmaceutical company AstraZeneca has started a global withdrawal of its COVID-19 vaccine, Vaxzevria, which has not been available in Australia since March 2023. Pharmaceutical company AstraZeneca has started a global withdrawal of its COVID-19 vaccine, Vaxzevria, which has not been available in Australia since March 2023. AstraZeneca has initiated the worldwide withdrawal of its COVID-19 vaccine due to …

Covishield vaccine has had more benefits than risks, says study by Kozhikode doctors
7 months, 2 weeks ago

Covishield vaccine has had more benefits than risks, says study by Kozhikode doctors

The Hindu  

At a time when the safety aspects of the Covishield vaccine have kicked up a row, a retrospective study by two doctors from Kozhikode has claimed that its risks are minimal in view of the benefits. The controversy arose after pharmaceutical company AstraZeneca admitted in the High Court of London, United Kingdom, that its vaccine against COVID-19 had the potential …

PM Modi's photo removed from vaccine certificates amidst Covishield controversy
7 months, 3 weeks ago

PM Modi's photo removed from vaccine certificates amidst Covishield controversy

Deccan Chronicle  

New Delhi: Amidst the ongoing controversy surrounding the Covishield vaccine, Prime Minister Narendra Modi's photograph has been removed from Covid-19 vaccine certificates. While speculation arose linking this action to AstraZeneca's acknowledgment of rare blood clotting cases associated with the vaccine, official sources have attributed it to the implementation of the election model code of conduct. The court had dismissed a …

Covishield | Plea in Supreme Court for probe panel for vaccine’s ‘risk factors’
7 months, 3 weeks ago

Covishield | Plea in Supreme Court for probe panel for vaccine’s ‘risk factors’

The Hindu  

The controversy over the safety aspects of the Covishield vaccine reached the Supreme Court on Wednesday, May 1, 2024, with a petition seeking the constitution of an expert medical panel to study the risk factors. Now after the document filed in UK court by the developer of Covishield, we are compelled to think on the risk and hazardous consequences of …

Only 7 Out 10 Lakh May Face Clotting Risk Due to Covishield: Former ICMR Scientist
7 months, 3 weeks ago

Only 7 Out 10 Lakh May Face Clotting Risk Due to Covishield: Former ICMR Scientist

News 18  

Only seven to eight individuals out of 10 lakh, who receive the coronavirus vaccine Covishield, face the risk of experiencing a rare side effect known as thrombosis thrombocytopenia syndrome. India’s top epidemiologist, former ICMR scientist Dr Raman Gangakhedkar, said those who got this vaccine have “no risk at all”. Gangakhedkar, who is known for his simplistic approach to clearing complicated …

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns
7 months, 3 weeks ago

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns

India TV News  

In response to recent concerns regarding potential rare side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical company has underscored its unwavering commitment to patient safety while affirming the vaccine's overall safety profile. This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria "can, in very rare cases, …

AstraZeneca’s submission in U.K. court nothing new, say doctors over Covishield’s potential to cause blood clots
7 months, 3 weeks ago

AstraZeneca’s submission in U.K. court nothing new, say doctors over Covishield’s potential to cause blood clots

The Hindu  

Following pharmaceutical company AstraZeneca’s admission in U.K. court documents that its vaccine against COVID-19 has the potential to cause Thrombosis with Thrombocytopenia Syndrome, a rare side effect associated with blood clotting, doctors in India said this is not new information and that they are “well aware of the warning which has been available in India as an insert with the …

What study on Covishield versus Covaxin vaccine reveals
9 months, 2 weeks ago

What study on Covishield versus Covaxin vaccine reveals

The Hindu  

March 07, 2024 10:59 am | Updated March 09, 2024 10:53 am IST - Bengaluru A new study by a consortium of 11 institutes, led by scientists from the National Centre for Biological Sciences, has found that the Covishield vaccine demonstrated more robust immune responses compared to Covaxin. The key findings state that Covishield, leveraging a virus vector to deliver …

Updated COVID vaccines will be available later this week, recommended for everyone six months and up
1 year, 3 months ago

Updated COVID vaccines will be available later this week, recommended for everyone six months and up

Salon  

A new, fourth round of COVID-19 booster shots was approved Tuesday, following the recommendation of federal health agencies, which will make the vaccines available to Americans later this week. The Centers for Disease Control and Prevention followed suit this afternoon, with CDC director Mandy Cohen recommending updated vaccination for "everyone 6 months and older to better protect you and your …

Serum Institute of India to produce 5mn Covishield doses in two months
1 year, 8 months ago

Serum Institute of India to produce 5mn Covishield doses in two months

Hindustan Times  

Serum Institute of India chief executive officer Adar Poonawalla, while underlining that the current strain of Covid is mild and the demand for vaccine shots is low, said his firm will produce five to six million Covishield doses in the next two to three months and same amount of stock is already available for Covovax. According to Poonawalla, SII has …

India restarts Covid vaccine production as new infections soar 30% in one day
1 year, 8 months ago

India restarts Covid vaccine production as new infections soar 30% in one day

The Independent  

India is ramping up its vaccine production following a rapid surge in Covid-19 cases driven by a new subvariant dubbed Arcturus. The country recorded 10,158 news Covid cases on Thursday, a 30 per cent surge in one day, according to the federal health ministry data. The company stopped manufacturing Covishield in December 2021 due to dwindling demand and a low …

Serum Institute could resume Covishield production as Covid cases rise
1 year, 8 months ago

Serum Institute could resume Covishield production as Covid cases rise

Live Mint  

The Serum Institute of India could resume production of the Covishield Covid-19 vaccine as infections rise in the country, a company spokesperson said on Wednesday. Dr Amitav Banerjee - an epidemiologist who leads DY Patil Medical College in Pune has earlier said that Covishield carried a ‘double whammy of risk’. Many would perhaps not know that Covishield carries a DNA …

Covovax to be available on CoWIN as booster dose soon. Check details
1 year, 8 months ago

Covovax to be available on CoWIN as booster dose soon. Check details

Hindustan Times  

In view of rising cases of COVID-19 in various parts of the country, Union Health Minister Mansukh Mandaviya is learnt to have approved the inclusion of Serum Institute’s Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday. According to an official source, Singh had mentioned in his letter to the ministry that …

Serum institute seeks to add Covovax on CoWIN portal as booster dose for adults
1 year, 8 months ago

Serum institute seeks to add Covovax on CoWIN portal as booster dose for adults

Hindustan Times  

Amid rising coronavirus cases, the Serum Institute of India has written a letter to the Union health ministry seeking the inclusion of its COVID-19 vaccine Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday. The letter was written by Prakash Kumar Singh, Director, Serum Institute of India on March 27, they said. …

’Covishield shouldn’t have been rolled out’: Doctor flags ’severe’ side-effects
1 year, 10 months ago

’Covishield shouldn’t have been rolled out’: Doctor flags ’severe’ side-effects

Live Mint  

A well known British-Indian cardiologist has flagged the cardiovascular side effects of the Covishield vaccine. According to Dr Aseem Malhotra, the vaccine manufactured in India by the Serum Institute is ‘even worse’ than mRNA COVID-19 vaccines when it came to concerns such as heart attacks and strokes. Citing a comparison published in a peer-reviewed journal, he said that the Oxford-AstraZeneca …

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose
1 year, 11 months ago

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose

News 18  

The Drug Controller General of India has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday. Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India, had recently written to the DCGI for the approval …

COVID-19: Covovax vaccine to get approval as booster dose in 10-15 days, says Poonawalla
1 year, 11 months ago

COVID-19: Covovax vaccine to get approval as booster dose in 10-15 days, says Poonawalla

Firstpost  

Pune: Chief Executive Officer of Serum Institute of India, Adar Poonawalla, has said their Covovax vaccine will get approval as a booster dose against Covid-19 in the next 10 to 15 days. Poonawalla told the media that the vaccine works very well against the Omicron variant of coronavirus. Speaking to reporters on the sidelines of an event at the Bharati …

Covovax to get approval as booster in 10-15 days, says SII’s Adar Poonawalla
1 year, 11 months ago

Covovax to get approval as booster in 10-15 days, says SII’s Adar Poonawalla

Live Mint  

As India braces for a possible rise in COVID-19 cases, a new vaccine is set to join the ranks as booster this month. Serum Institute of India's Covovax vaccine - which is effective against the Omicron strains - will get approval as a booster jab against COVID-19 in the next 10 to 15 days. All you need to know about …

Covovax more efficient than Covishield against new variant: Poonawalla
1 year, 11 months ago

Covovax more efficient than Covishield against new variant: Poonawalla

Hindustan Times  

Adar Poonawalla, Chief executive Officer at Serum Institute of India said Covovax has better efficacy than the Covishield vaccine against the new covid variant. NCP chief Sharad Pawar, Deputy Chief Minister Devendra and Adar Poonawalla at the Inauguration Bharti Vidyapeeth Super Speciality Hospita at Bharti Vidyapeeth, Katraj on Sunday. And we are hopeful that the permission will be granted soon …

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose
2 years ago

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose

News 18  

The Serum Institute of India has sought the drug regulator’s approval for market authorisation of its COVID-19 vaccine Covovax as a booster dose for those aged 18 years and above who have been administered two doses of Covishield or Covaxin, official sources said on Thursday. Prakash Kumar Singh, director, government and regulatory affairs, SII, submitted a market authorisation application for …

India need not panic given excellent COVID-19 vaccination coverage: Adar Poonawalla
2 years ago

India need not panic given excellent COVID-19 vaccination coverage: Adar Poonawalla

The Hindu  

Serum Institute of India CEO Adar Poonawalla on Tuesday expressed concern over reports of a rising COVID-19 graph in China but said there is no need to panic as the vaccination coverage in India is excellent. Mr. Poonawalla's tweet came a day after the Union Health Ministry urged all states and UTs to ramp up the whole genome sequencing of …

SII stopped Covishield production last year; says Adar Poonawalla; claims nearly 100 million doses expired
2 years, 2 months ago

SII stopped Covishield production last year; says Adar Poonawalla; claims nearly 100 million doses expired

India TV News  

Highlights Adar Poonawalla said SII halted the production of vaccines in December 2021 Booster vaccines have no demand, Adar Poonawalla said There is general lethargy among people and they are fed up with the pandemic, Poonawalla said Serum Institute of India has stopped the production of the Covishield vaccine as there are not many takers for COVID-19 booster doses. The …

COVID-19: Corbevax to be given as boosters at vaccination centres from today
2 years, 4 months ago

COVID-19: Corbevax to be given as boosters at vaccination centres from today

Live Mint  

Hyderabad based-Biological E Ltd 's recently approved heterologous Covid-19 vaccine Corbevax to be available as a booster dose on the COWIN App in both public and private vaccination centres from 12 August, the firm said on 11 August. The Union Health Ministry approved Corbevax as India's first heterologous COVID-19 booster shot for 18 years and above after the six months …

Corbevax Likely to be Available As Covid Booster Dose at Vaccination Centres from Friday
2 years, 4 months ago

Corbevax Likely to be Available As Covid Booster Dose at Vaccination Centres from Friday

News 18  

Biological E. Ltd on Thursday said it has delivered 10 crore doses of its Covid-19 vaccine, Corbevax to the Centre so far which is expected to be available as a booster dose on the Cowin App in public and private vaccination centers from Friday. Corbevax was also approved by the Union Health Ministry as a heterologous Covid-19 booster dose under …

Corbevax as Covid booster for adults from August 12. Check details
2 years, 4 months ago

Corbevax as Covid booster for adults from August 12. Check details

India Today  

In a boost to India’s fight against coronavirus, the government gave nod to Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Announcing the decision, Union Health minister Mansukh Mandaviya said, “Further Strengthening India's arsenal against Covid-19, Ministry of Health and Family Welfare approves Corbevax as precaution dose for those …

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report
2 years, 4 months ago

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report

Live Mint  

The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, news agency PTI has reported on 10 August citing official sources. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of …

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients
2 years, 4 months ago

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients

News 18  

The Centre has approved Biological E’s Corbevax as a Covid-19 precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Union Health Secretary Rajesh Bhushan said, “Corbevax will be available as precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines …

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
2 years, 4 months ago

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

India TV News  

Highlights Biological E's Corbevax has been approved as a booster or precaution dose. Covid vaccination: Biological E's Corbevax has been approved as a booster or precaution dose for those above the age of 18, and those who are fully vaccinated with either Covishield or Covaxin. "Corbevax will be considered as a precaution dose after completion of six months or 26 …

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon
2 years, 4 months ago

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon

News 18  

The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday. “Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose …

Adults may get different vaccine as booster shot instead of Covishield, Covaxin
2 years, 4 months ago

Adults may get different vaccine as booster shot instead of Covishield, Covaxin

Live Mint  

As the government has continued to emphasize Covid booster doses due to the rising number of cases, a panel has recommended a different vaccine for Indian adults. Government panel National Technical Advisory Group on Immunisation has recommended Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin. "Corbevax may be considered for a third/precaution …

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership
2 years, 5 months ago

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership

News 18  

India has crossed record 200 crore mark in Covid-19 vaccinations within 18 months of launching the inoculation exercise in January last year. #200CroreVaccinations https://t.co/FtobFYBprV— Dr Mansukh Mandaviya July 17, 2022 A seven-phase vaccination drive was followed on the principle of Prioritization for Vaccine Administration based on scientific advice and global best practices, government officials told News18. While some experts had …

Serum Institute gets govt nod to export 32.4 lakh doses of Covovax vaccine to US
2 years, 5 months ago

Serum Institute gets govt nod to export 32.4 lakh doses of Covovax vaccine to US

India Today  

The government has allowed Serum Institute of India to supply 32.4 lakh doses of its Covid-19 jab Covovax under the brand name Nuvaxovid to the US, which will be the first vaccine to be exported to the country by any Indian manufacturer, official sources said on Friday. "It is a matter of pride for us and our country that, in …

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI
2 years, 5 months ago

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI

The Hindu  

Allowing Biological E’s Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said. “The National Technical Advisory Group on Immunisation will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated …

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin
2 years, 6 months ago

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin

The Hindu  

Hyderabad-based Biological E. Limited ’s COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India as a heterologous COVID-19 booster dose to individuals aged 18 years and above after 6 months of administration of primary vaccination of Covaxin or Covishield vaccines for restricted use in emergency situations. ‘’Recently, BE furnished its clinical trials data to the DCGI, …

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above
2 years, 6 months ago

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above

ABP News  

New Delhi: The Drug Controller General of India approved the Corbevax Covid-19 booster as heterologous Covid-19 booster dose for adults above the age of 18 years who got their primary Covid-19 vaccination of Covishield or Covaxin administered six months before, reported news agency ANI. Recently, BE has furnished its clinical trials data to the DCGI who after a detailed evaluation …

SII has stockpile of 200 mn doses; India better prepared to fight Covid: CEO
2 years, 8 months ago

SII has stockpile of 200 mn doses; India better prepared to fight Covid: CEO

Hindustan Times  

Chief executive officer of Serum Institute of India Adar Poonawalla on Tuesday said the company has a stockpile of 200 million doses of Covishield, while it has already exported 40 million doses of Covovax to European countries and Australia. Serum Institute of India CEO Adar Poonawalla speaks at the 'AIMA Leadership Conclave' in New Delhi on Tuesday, "We have a …

Serum Institute to Give Free Covishield Vials to Private Vaccination Centres to Compensate for Price Difference
2 years, 8 months ago

Serum Institute to Give Free Covishield Vials to Private Vaccination Centres to Compensate for Price Difference

News 18  

A day after slashing the price of the precaution dose of Covishield to Rs 225 per shot for private hospitals, the Serum Institute of India told the Centre on Sunday that it will compensate for the price difference for the unexpired stocks lying with private centres in the form of free vials of fresh stocks, official sources said. Vaccine majors …

Covishield, Covaxin to now cost private hospitals Rs 225 per dose
2 years, 8 months ago

Covishield, Covaxin to now cost private hospitals Rs 225 per dose

India Today  

A single dose of the Serum Institute of India's Covishield and Bharat Biotech's Covaxin will now cost private hospitals Rs 225. Adar Poonawalla, CEO of SII, said in a tweet on Saturday that the vaccine maker has decided to slash the prices of the Covid-19 jab for private hospitals from Rs 600 to Rs 225 after consultation with the central …

Covishield booster shots to be priced at ₹600 plus taxes: Adar Poonawalla
2 years, 8 months ago

Covishield booster shots to be priced at ₹600 plus taxes: Adar Poonawalla

Hindustan Times  

The Union health ministry announced on Friday that beginning April 10, booster doses will be available to all adults at private Covid-19 vaccine centres. Soon after, Serum Institute of India CEO Adar Poonawalla said Covishield precautionary for all adults will be priced at ₹600 per shot plus taxes. Meanwhile, Covovax - which has not been formally announced as a booster …

Serum Institute's Covishield precaution dose priced at Rs 600 per shot
2 years, 8 months ago

Serum Institute's Covishield precaution dose priced at Rs 600 per shot

India TV News  

Highlights SII said precaution dose of its Covishield vaccine against COVID will be priced at Rs 600 per shot Hospitals will get at discounted price More than 2.4 crore precaution doses have also been administered Vaccine maker Serum Institute of India on Friday said the precaution dose of its Covishield vaccine against COVID-19 will be priced at Rs 600 per …

India's drugs regulator approves phase-3 trial of covid vaccine covovax
2 years, 9 months ago

India's drugs regulator approves phase-3 trial of covid vaccine covovax

India Today  

The Drugs Controller General of India granted permission on Wednesday for conducting the phase-3 clinical trial of Covid-19 vaccine Covovax as a booster dose in adults, official sources said. The Subject Expert Committee on Covid-19 of the Central Drugs Standard Control Organisation had, on March 5, recommended permission for conducting the phase-3 clinical trial for Covovax as a booster dose …

Corbevax safe for kids, offers high antibody levels, says Biological E CEO | EXCLUSIVE
2 years, 9 months ago

Corbevax safe for kids, offers high antibody levels, says Biological E CEO | EXCLUSIVE

India Today  

India's third homegrown Covid-19 vaccine, Corbevax, is safe and offers good immunogenicity and higher antibody levels than some other vector vaccines, said Mahima Datla, managing director of Biological E. Limited on Wednesday. THE CORBEVAX CONTROVERSY Asked how effective the vaccine will be against Omicron, the latest strain to emerge which drove the third wave in, Datla said it was a …

Discover Related